
Dapinder Singh
Examiner (ID: 7865, Phone: (571)270-1774 , Office: P/3748 )
| Most Active Art Unit | 3746 |
| Art Unit(s) | 3746, 3748 |
| Total Applications | 1196 |
| Issued Applications | 994 |
| Pending Applications | 73 |
| Abandoned Applications | 157 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16466688
[patent_doc_number] => 20200368225
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF DEPRESSION, ANXIETY, AND NEURODEGENERATIVE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/724903
[patent_app_country] => US
[patent_app_date] => 2019-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29075
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16724903
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/724903 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF DEPRESSION, ANXIETY, AND NEURODEGENERATIVE DISORDERS | Dec 22, 2019 | Abandoned |
Array
(
[id] => 20432181
[patent_doc_number] => 12501900
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-23
[patent_title] => Heterocyclyl pyridazine as fungicidal compounds
[patent_app_type] => utility
[patent_app_number] => 17/309764
[patent_app_country] => US
[patent_app_date] => 2019-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 132888
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17309764
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/309764 | Heterocyclyl pyridazine as fungicidal compounds | Dec 18, 2019 | Issued |
Array
(
[id] => 15796957
[patent_doc_number] => 20200121621
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-23
[patent_title] => METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS
[patent_app_type] => utility
[patent_app_number] => 16/721329
[patent_app_country] => US
[patent_app_date] => 2019-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10657
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16721329
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/721329 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | Dec 18, 2019 | Abandoned |
Array
(
[id] => 16435608
[patent_doc_number] => 20200352933
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-12
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA
[patent_app_type] => utility
[patent_app_number] => 16/710091
[patent_app_country] => US
[patent_app_date] => 2019-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22209
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16710091
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/710091 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA | Dec 10, 2019 | Abandoned |
Array
(
[id] => 17356724
[patent_doc_number] => 20220017520
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => MACROCYCLIC COMPOUND AS CDK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE
[patent_app_type] => utility
[patent_app_number] => 17/413262
[patent_app_country] => US
[patent_app_date] => 2019-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12051
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 591
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17413262
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/413262 | MACROCYCLIC COMPOUND AS CDK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | Dec 10, 2019 | Pending |
Array
(
[id] => 16883588
[patent_doc_number] => 20210169783
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-10
[patent_title] => ORAL PRODUCTS WITH CONTROLLED RELEASE
[patent_app_type] => utility
[patent_app_number] => 16/707064
[patent_app_country] => US
[patent_app_date] => 2019-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13414
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16707064
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/707064 | ORAL PRODUCTS WITH CONTROLLED RELEASE | Dec 8, 2019 | Pending |
Array
(
[id] => 15996259
[patent_doc_number] => 20200174000
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-04
[patent_title] => MATERIALS AND METHODS FOR DETECTING AND/OR TREATING DUCTAL CARCINOMA IN SITU AND RELATED SYMPTOMS
[patent_app_type] => utility
[patent_app_number] => 16/700157
[patent_app_country] => US
[patent_app_date] => 2019-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7199
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700157
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/700157 | MATERIALS AND METHODS FOR DETECTING AND/OR TREATING DUCTAL CARCINOMA IN SITU AND RELATED SYMPTOMS | Dec 1, 2019 | Abandoned |
Array
(
[id] => 17297758
[patent_doc_number] => 20210393597
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => TARGETING THE TRANSCRIPTION FACTOR NF-KB WITH HARMINE
[patent_app_type] => utility
[patent_app_number] => 17/289816
[patent_app_country] => US
[patent_app_date] => 2019-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25022
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289816
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/289816 | TARGETING THE TRANSCRIPTION FACTOR NF-KB WITH HARMINE | Nov 6, 2019 | Abandoned |
Array
(
[id] => 15960413
[patent_doc_number] => 20200163958
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-28
[patent_title] => USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION
[patent_app_type] => utility
[patent_app_number] => 16/667300
[patent_app_country] => US
[patent_app_date] => 2019-10-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37301
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16667300
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/667300 | USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION | Oct 28, 2019 | Abandoned |
Array
(
[id] => 16310761
[patent_doc_number] => 20200289499
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING A DEXTROMETHORPHAN COMPOUND AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA
[patent_app_type] => utility
[patent_app_number] => 16/596236
[patent_app_country] => US
[patent_app_date] => 2019-10-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27327
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16596236
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/596236 | PHARMACEUTICAL COMPOSITIONS COMPRISING A DEXTROMETHORPHAN COMPOUND AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA | Oct 7, 2019 | Abandoned |
Array
(
[id] => 16282583
[patent_doc_number] => 20200276185
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-03
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/591879
[patent_app_country] => US
[patent_app_date] => 2019-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30943
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16591879
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/591879 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Oct 2, 2019 | Abandoned |
Array
(
[id] => 19058911
[patent_doc_number] => 11938103
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-26
[patent_title] => Potentiation of helminth treatment
[patent_app_type] => utility
[patent_app_number] => 17/281914
[patent_app_country] => US
[patent_app_date] => 2019-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7794
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17281914
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/281914 | Potentiation of helminth treatment | Sep 29, 2019 | Issued |
Array
(
[id] => 16204859
[patent_doc_number] => 20200237849
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/584667
[patent_app_country] => US
[patent_app_date] => 2019-09-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38640
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16584667
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/584667 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | Sep 25, 2019 | Abandoned |
Array
(
[id] => 15492997
[patent_doc_number] => 20200046687
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-13
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING PAIN
[patent_app_type] => utility
[patent_app_number] => 16/584103
[patent_app_country] => US
[patent_app_date] => 2019-09-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16985
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16584103
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/584103 | Methods and compositions for treating pain | Sep 25, 2019 | Issued |
Array
(
[id] => 17297792
[patent_doc_number] => 20210393631
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => INTEGRASE INHIBITORS FOR THE PREVENTION OF HIV
[patent_app_type] => utility
[patent_app_number] => 17/278186
[patent_app_country] => US
[patent_app_date] => 2019-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18987
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -72
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278186
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/278186 | INTEGRASE INHIBITORS FOR THE PREVENTION OF HIV | Sep 17, 2019 | Abandoned |
Array
(
[id] => 15323995
[patent_doc_number] => 20200002327
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-02
[patent_title] => THERAPEUTIC AGENT FOR ANXIETY DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/568827
[patent_app_country] => US
[patent_app_date] => 2019-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14201
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16568827
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/568827 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | Sep 11, 2019 | Abandoned |
Array
(
[id] => 17482095
[patent_doc_number] => 20220089599
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-24
[patent_title] => ALKYNYL NICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/274950
[patent_app_country] => US
[patent_app_date] => 2019-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11719
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -38
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17274950
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/274950 | ALKYNYL NICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS | Sep 11, 2019 | Pending |
Array
(
[id] => 16686688
[patent_doc_number] => 20210069163
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => ANTICANCER COMBINATION OF CHIDAMIDE AND CELECOXIB SALTS
[patent_app_type] => utility
[patent_app_number] => 16/566744
[patent_app_country] => US
[patent_app_date] => 2019-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16908
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16566744
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/566744 | Anticancer combination of chidamide and celecoxib salts | Sep 9, 2019 | Issued |
Array
(
[id] => 15342385
[patent_doc_number] => 20200009084
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-09
[patent_title] => METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS
[patent_app_type] => utility
[patent_app_number] => 16/549828
[patent_app_country] => US
[patent_app_date] => 2019-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14849
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 229
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16549828
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/549828 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | Aug 22, 2019 | Abandoned |
Array
(
[id] => 16252065
[patent_doc_number] => 20200261439
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-20
[patent_title] => NICOTINE FORMULATION FOR ACTIVE MESH NEBULIZER
[patent_app_type] => utility
[patent_app_number] => 16/547478
[patent_app_country] => US
[patent_app_date] => 2019-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3421
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16547478
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/547478 | NICOTINE FORMULATION FOR ACTIVE MESH NEBULIZER | Aug 20, 2019 | Abandoned |